This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record. Numerical trial results on this page are restricted to the results posted in the ClinicalTrials.gov record; calculations added by Clinical Biostats are labelled as such.
1. Trial at a Glance
This page covers the registry results for ACCESS-Europe A Two-Phase Observational Study of the MitraClip® System in Europe (NCT01288976), a registered phase not stated study. The primary outcome is MR Severity.
| Feature | Registry value |
|---|---|
| ClinicalTrials.gov identifier | NCT01288976 |
| Phase | Phase not stated |
| Condition | Mitral Valve (MV) Regurgitation |
| Allocation | Not Stated |
| Design model | Not Stated |
| Masking | Not Stated |
| Enrollment | 721 |
| Arms in the primary outcome | n/a |
| Lead sponsor | Abbott Medical Devices |
| Results posted | Yes |
2. Clinical Question
Population
The study concerns patients with mitral valve regurgitation (MR) treated in European clinical practice. The registry record lists enrollment of 721. The baseline MR severity description notes that some patients were excluded from the analysis population, but the final text describing the reasons is incomplete.
Intervention
The intervention of interest is MitraClip therapy. The registry describes patients in this arm as treated with the MitraClip System. The study is observational, so treatment was not assigned through a randomized comparison.
Comparator
The registry also lists Medical Management and Mitral Valve Surgery. Medical management is described as nonsurgical care based on standard hospital clinical practice; surgery is described as repair or replacement based on standard hospital clinical practice. These arms are not like-for-like controls for the MitraClip group.
Primary question
The primary outcome is MR severity, assessed by echocardiography at baseline and expressed as the percentage of participants. The registry describes severity grading from 0+ through 4+, but does not report the primary outcome values for the groups in this record. It states that MR severity was not consistently captured in the comparator groups.
The study summary says it was designed to observe outcomes through 12-months among patients treated with MitraClip and patients treated with alternative therapies. That broad aim should be distinguished from the listed primary outcome: the recorded primary measure is baseline MR severity, not a reported comparison of outcomes through follow-up. The record explains that the comparator groups were followed and studied primarily from a health economic perspective, and that clinical outcomes at follow-up are limited and have not been validated. It also states that clinical outcomes for those groups will not be reported. Consequently, the registry information does not support a complete clinical comparison across the three treatment groups.
3. Trial Design
ACCESS-Europe is identified in the registry as a two-phase observational study of the MitraClip System in Europe. Its status is completed. The record lists the study start as 2008-10 and primary completion as 2012-06. It names Abbott Medical Devices as sponsor and lists mitral valve regurgitation as the condition. The detailed meaning of the study’s phases, including their procedures or timing, is not reported in the registry record.
The three groups reflect treatment received in clinical practice: MitraClip Therapy, Medical Management, and Mitral Valve Surgery. The record describes medical management as nonsurgical care under standard hospital clinical practice and surgery as repair or replacement under standard hospital clinical practice. Allocation is not stated. The registry characterizes the study as nonrandomized and cautions that the arms are not a like-for-like control comparison. This matters because treatment groups in an observational study may differ in ways that also affect outcomes. The record does not report a method for adjusting for those differences.
Enrollment is listed as 721, but that figure should not be read as the number contributing to every outcome. The primary outcome description says that a total of 240 patients were excluded from its analysis population for reasons that include death, withdrawal of consent, and loss to follow-up; the final listed reason is truncated in the record. Outcome-specific analysis counts are not reported in the registry record for the primary endpoint.
The study summary describes observation of outcomes through 12-months. The primary outcome itself is MR severity at baseline. The record lists additional outcomes including procedure characteristics, hospital stay, discharge information, discharge MR severity, and Kaplan-Meier freedom from all-cause mortality. It reports 22 outcome measures and 0 analyses. Those entries indicate the scope of registered outcomes, but do not supply a complete set of comparative clinical results.
4. Participant Flow and Accounting
The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.
Overall Study
| Stage | MitraClip Therapy | Medical Management | Mitral Valve Surgery |
|---|---|---|---|
| STARTED | 567 | 49 | 105 |
| COMPLETED | 389 | 22 | 85 |
| NOT COMPLETED | 178 | 27 | 20 |
Reasons for not completing this period:
| Reason | MitraClip Therapy | Medical Management | Mitral Valve Surgery |
|---|---|---|---|
| Withdrawal by Subject | 58 | 12 | 9 |
| Death | 98 | 6 | 4 |
| Data unavailable | 22 | 9 | 7 |
Analysis population for the primary outcome, as defined in the registry: MR severity was not consistently captured for patients in the Medical Management and Mitral Valve Surgery groups. MR severity will not be reported for these comparator arms. A total of 240 patients excluded from analysis population due to death:98, withdrew consent:58, lost to follow-up:22 and missed mitral regurgitation evaluation:62 at baseline.
5. Baseline Characteristics
The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.
| Characteristic | Unit | MitraClip Therapy | Medical Management | Mitral Valve Surgery | Total |
|---|---|---|---|---|---|
| Participants analysed | 567 | 49 | 105 | 721 | |
| Age, Continuous | years | 73.7 (SD 9.6) | 70.7 (SD 12.6) | 60.0 (SD 15.2) | 68.1 (SD 12.4) |
| Sex: Female, Male: Female | Participants | 205 | 23 | 46 | 274 |
| Sex: Female, Male: Male | Participants | 362 | 26 | 59 | 447 |
| Region of Enrollment: Europe | participants | 567 | 49 | 105 | 721 |
6. Primary Endpoint
The registry lists the primary outcome as MR Severity, measured over At baseline.
| Element | Registry entry |
|---|---|
| Result type | Number |
| Measure of spread | not applicable |
| Unit | percentage of participants |
| Endpoint classification | Binary Endpoint |
The primary outcome is MR severity at baseline, measured as the percentage of participants in severity categories. The registry defines severity as site-assessed mitral regurgitation evaluated by echocardiography. The grading scale runs from 0+ to 4+: 0+ denotes absence of mitral regurgitation; 1+ is mild; 1+ to 2+ is mild-to-moderate; 2+ to 3+ is moderate to moderate-to-severe; 3+ is moderate-to-severe; 3+ to 4+ is moderate-to-severe to severe; and 4+ is severe.
Severity grading provides a clinical description of the condition at the recorded baseline assessment. Expressing categories as percentages can make the distribution of severity easier to interpret than a list of raw counts alone. It does not, by itself, show whether severity changes after treatment or whether one treatment leads to a different outcome than another. Such conclusions would require comparable measurements at relevant time points and appropriate analysis.
The registry record says MR severity was not consistently captured for patients in the Medical Management and Mitral Valve Surgery groups, and that severity will not be reported for those comparator arms. The available record does not include the baseline severity percentages for the MitraClip group or other primary-outcome values. Those values are therefore not reported in the registry record. The stated endpoint and its clinical definition should not be mistaken for a reported result.
7. Why No Re-analysis Is Shown
8. Statistical Interpretation
The central interpretive issue is the gap between the study’s broad observational aim and the clinical results available in the registry record. The summary describes observation of outcomes through 12-months among patients receiving MitraClip or alternative therapies. The registered primary outcome, however, is baseline MR severity. The record does not include the group-level baseline severity values, and it says that severity was not consistently captured in the Medical Management and Mitral Valve Surgery groups. It therefore does not provide a comparable baseline distribution across all listed groups.
The registry lists enrollment of 721 and says that 240 patients were excluded from the primary outcome analysis population for reasons that include death, withdrawal of consent, and loss to follow-up. The remaining reason in the description is cut off. The record does not provide enough detail to reconstruct the analysis population or determine outcome-specific denominators from that description. Enrollment alone cannot be treated as the denominator for every outcome.
The study is observational, allocation is not stated, and the record explicitly warns that the arms are not a like-for-like control comparison. Treatment choice in ordinary clinical practice can be related to patient characteristics and clinical circumstances. If those factors also relate to outcomes, a simple difference between groups would not necessarily represent an effect caused by treatment. The registry record does not report an adjustment strategy or comparative estimates that would address this concern.
Clinical outcome information for the comparator arms is described as limited and not validated, and the record says those clinical outcomes will not be reported. The adverse-event entries do provide counts for each group, but those figures are not a substitute for a complete, adjusted comparison. The available information does not establish that the groups had the same observation period, risk profile, or completeness of event capture. Those details are not reported in the registry record.
The record lists 22 outcome measures and 0 analyses. It does not report primary-outcome estimates, confidence intervals, hypothesis tests, or comparative effect estimates in the registry record for this analysis. Without such results, statistical precision and the compatibility of observed data with different possible effects cannot be assessed. The responsible reading is descriptive: the registry documents the study’s structure, its stated outcome definitions, and some adverse-event counts, while leaving important comparative clinical results unavailable.
These limitations do not show that no analyses were conducted outside the registry. They mean that analyses, methods, and results not present in the registry record cannot be used to draw conclusions from this record. In particular, no causal conclusion about treatment differences follows from the reported group descriptions or event counts alone.
9. Statistical Methods Explained
The registry identifies an observational study with three treatment groups and does not state allocation. Statistical interpretation therefore begins by separating description from causal comparison. The group labels identify treatments received; they do not establish that participants were exchangeable at baseline or that treatment assignment was independent of clinical characteristics. The record also cautions that the arms are not a like-for-like control comparison.
What does a percentage describe?
The primary outcome is MR severity expressed as the percentage of participants in severity categories. A percentage describes the share of the analyzed group recorded in a category, using the relevant group denominator. Its interpretation depends on knowing who was included and whether measurements were available. The registry record does not report the primary outcome percentages or the relevant outcome-specific denominators. It says severity was not consistently captured in the two comparator groups, so a complete distribution across all treatment groups is not available.
The severity scale is ordinal: its categories represent increasing degrees of MR, but the spacing between categories is not presented as equal. Treating the category labels as if each step represented the same quantitative change would require an assumption not stated in the registry record. Reporting category percentages preserves the recorded classifications without implying equal distances between them.
Why does observational allocation matter?
In general, random assignment can help balance measured and unmeasured prognostic factors across groups, while observational treatment selection does not guarantee that balance. In an observational comparison, differences in outcomes may reflect treatment, baseline risk, clinical decisions, or other factors. Statistical adjustment can address measured differences when the relevant data and a suitable model are available, but it cannot automatically remove bias from unmeasured or poorly measured factors. The adjustment methods, covariates, and comparative models are not reported in the registry record.
The description that treatment was based on standard hospital clinical practice is consistent with treatment groups arising in clinical care rather than from a stated randomized assignment. It does not explain the criteria used to choose treatment for each patient. Those criteria are not reported in the registry record. Accordingly, group differences should be read as descriptive unless an adequately documented analysis supports a stronger interpretation.
What would uncertainty estimates add?
In general, a confidence interval communicates the range of effect estimates compatible with the data under the specified statistical method. A narrow interval indicates greater precision than a wide interval, while neither width nor location alone resolves bias in an observational comparison. Confidence intervals for the primary outcome and comparative effects are not reported in the registry record. No p-values or other hypothesis-test results are reported in the information.
Statistical significance and clinical importance are distinct ideas in general. A test result does not indicate whether an effect is meaningful in practice, and an imprecise estimate may leave several possibilities compatible with the data. For this study, the absence of reported comparative estimates means that neither statistical significance nor effect magnitude can be evaluated from the registry information.
How should the adverse-event counts be read?
The registry lists counts of participants at risk and participants affected by serious and other adverse events for each group, along with death counts. These are descriptive entries. A count is not a rate unless its relevant time at risk and observation context are specified. The record does not state event-specific follow-up time or provide an adjusted comparison. It also does not establish from the available information whether participants could contribute to more than one listed event category. As a general principle, multiple events or categories may overlap unless the reporting rules say otherwise.
The serious-event terms are listed with percentages, including Atrial arrhythmias, Heart Failure, and Breathing abnormalities. The denominator and detailed calculation for those percentages are not reported in the registry record. These listed percentages should therefore be read as the registry’s reported figures, not as independently interpretable risks or mutually exclusive portions of the groups.
What do the planning illustrations mean?
In general, sample-size planning estimates how many participants may be needed to detect a prespecified effect under stated assumptions. The record describes planning illustrations based on the observed effect, a two-sided significance level of 0.05, equal allocation between two arms, and a normal approximation. It says the target effect is a stated fraction of the observed effect. These are planning illustrations, not observed power, and they are not the study’s own design justification. The record does not report the study’s sample-size justification. The actual illustration values and the underlying observed effect are not reported in the registry information used for this analysis.
Planning values depend on the assumptions used, including the size of the effect to detect, outcome variability, allocation, and analysis method. Changing an assumption can change the planning estimate. The illustrations cannot establish that the completed study had a particular probability of detecting an effect, nor can they replace reported estimates and uncertainty intervals. The record’s description specifies participants per arm for the non-time-to-event planning illustrations and total events for time-to-event illustrations.
Finally, the registry lists 22 outcome measures but 0 analyses. This indicates that outcome registration should not be confused with reported statistical analysis. The analysis plan, multiplicity handling, missing-data methods, and outcome-specific models are not reported in the registry record. Without those details and the corresponding results, the statistical methods cannot be fully assessed.
10. Multiplicity, Missing Data and Analysis Populations
The registry lists 22 outcome measures and 0 analyses. The record does not describe a multiplicity strategy, such as prioritizing a limited set of confirmatory tests or adjusting interpretation when many outcomes are examined. In general, evaluating numerous outcomes can increase the chance of finding an apparently notable result by chance if each is tested separately. That general concern does not establish that a particular error occurred in this study; the analysis details are not reported in the registry record.
The primary outcome description states that a total of 240 patients were excluded from its analysis population because of reasons including death, withdrawal of consent, and loss to follow-up. The last listed reason is truncated in the record. The primary-outcome population definition, the outcome-specific denominators, and the timing of exclusions are not reported in sufficient detail in the registry record to reconstruct who contributed to each analysis. Enrollment of 721 should not be treated as an analysis denominator.
In general, missing outcome data can affect both precision and validity. The effect depends on why values are missing and how missingness relates to participants’ characteristics and outcomes. Statistical methods can address some missing-data situations under stated assumptions, but no missing-data method or sensitivity analysis is reported in the registry record.
The record specifically notes inconsistent MR severity capture in the Medical Management and Mitral Valve Surgery groups, limited and unvalidated follow-up clinical outcomes for comparator groups, and that comparator clinical outcomes will not be reported. These are important limits on outcome completeness and comparability. A prespecified analysis population, missingness assessment, and transparent account of available measurements would be needed to evaluate the consequences; those details are not reported in the registry record.
11. Safety Results
The registry reports serious adverse events as affected participants divided by participants at risk.
| Arm | Participants with serious adverse events | Participants at risk | Percentage |
|---|---|---|---|
| MitraClip Therapy | 371 | 567 | 65.4% |
| Medical Management | 21 | 49 | 42.9% |
| Mitral Valve Surgery | 58 | 105 | 55.2% |
Deaths
| Arm | Deaths (participants affected of at risk) |
|---|---|
| MitraClip Therapy | 13 of 567 |
| Medical Management | 1 of 49 |
| Mitral Valve Surgery | 2 of 105 |
Other (non-serious) adverse events
Participants with at least one non-serious event at or above the registry's 0% reporting threshold.
| Arm | Participants affected of at risk |
|---|---|
| MitraClip Therapy | 367 of 567 |
| Medical Management | 20 of 49 |
| Mitral Valve Surgery | 56 of 105 |
Most frequent serious adverse event terms
| Event term | Organ system | MitraClip Therapy | Medical Management | Mitral Valve Surgery |
|---|---|---|---|---|
| Heart Failure | Cardiac disorders | 98 of 567 | 3 of 49 | 1 of 105 |
| Breathing abnormalities | Respiratory, thoracic and mediastinal disorders | 76 of 567 | 1 of 49 | 0 of 105 |
| Atrial arrhythmias | Cardiac disorders | 45 of 567 | 5 of 49 | 20 of 105 |
| Anemia | Blood and lymphatic system disorders | 57 of 567 | 1 of 49 | 8 of 105 |
| Miscellaneous:other | General disorders | 55 of 567 | 4 of 49 | 6 of 105 |
| Renal failure | Renal and urinary disorders | 47 of 567 | 2 of 49 | 7 of 105 |
| Metabolic/Endocrine disorders | Metabolism and nutrition disorders | 42 of 567 | 5 of 49 | 2 of 105 |
| Edema | Vascular disorders | 45 of 567 | 0 of 49 | 2 of 105 |
| Hematologic Miscellaneous | Blood and lymphatic system disorders | 40 of 567 | 3 of 49 | 2 of 105 |
| Pleural Effusion | Respiratory, thoracic and mediastinal disorders | 33 of 567 | 2 of 49 | 4 of 105 |
Most frequent non-serious adverse event terms
| Event term | Organ system | MitraClip Therapy | Medical Management | Mitral Valve Surgery |
|---|---|---|---|---|
| Heart Failure | Cardiac disorders | 98 of 567 | 3 of 49 | 1 of 105 |
| Breathing abnormalities | Respiratory, thoracic and mediastinal disorders | 76 of 567 | 1 of 49 | 0 of 105 |
| Atrial arrhythmias | Cardiac disorders | 45 of 567 | 5 of 49 | 20 of 105 |
| Anemia | Blood and lymphatic system disorders | 57 of 567 | 1 of 49 | 8 of 105 |
| Miscellaneous : other | General disorders | 55 of 567 | 4 of 49 | 6 of 105 |
| Renal failure | Renal and urinary disorders | 47 of 567 | 2 of 49 | 7 of 105 |
| Metabolic/Endocrine disorders | Metabolism and nutrition disorders | 42 of 567 | 5 of 49 | 2 of 105 |
| Edema | Vascular disorders | 45 of 567 | 0 of 49 | 2 of 105 |
| Hematologic Miscellaneous | Blood and lymphatic system disorders | 40 of 567 | 3 of 49 | 2 of 105 |
| Pleural Effusion | Respiratory, thoracic and mediastinal disorders | 33 of 567 | 2 of 49 | 4 of 105 |
Serious events with the highest arm-level rate: atrial arrhythmias (19.0%), heart failure (17.3%), breathing abnormalities (13.4%), metabolic/endocrine disorders (10.2%), anemia (10.1%).
The adverse-event information is listed separately for MitraClip Therapy, Medical Management, and Mitral Valve Surgery. For serious adverse events, the registry lists 567 at risk and 371 affected in MitraClip Therapy, 49 at risk and 21 affected in Medical Management, and 105 at risk and 58 affected in Mitral Valve Surgery. For other adverse events, it lists 567 at risk and 367 affected, 49 at risk and 20 affected, and 105 at risk and 56 affected, respectively. Death counts are listed as 13, 1, and 2 in the same group order.
These are registry counts, not a randomized comparison. The groups differ in size, and the record does not provide the event observation time, adjusted estimates, or uncertainty intervals needed to interpret differences as comparative risks. The adverse-event information should not be treated as proof that one group had a higher or lower underlying risk. The record also lists serious-event terms with percentages: Atrial arrhythmias at 19.0%, Heart Failure at 17.3%, Breathing abnormalities at 13.4%, Metabolic/Endocrine disorders at 10.2%, Anemia at 10.1%, and Miscellaneous:other at 9.7%. Their denominator and category-overlap rules are not reported in the registry record.
12. What the Result Does, and Does Not, Mean
The registry record documents an observational study of MitraClip therapy alongside Medical Management and Mitral Valve Surgery. It provides a definition for baseline MR severity and reports some adverse-event counts. It also describes the study’s intended observation of outcomes through 12-months. These registry entries help establish what the study set out to observe and what types of information the registry records.
The information does not provide the baseline MR severity percentages for the primary outcome. Nor does it provide a complete, validated clinical outcome comparison across the treatment groups. The record says MR severity was not consistently captured in the comparator groups and that comparator clinical outcomes at follow-up are limited, have not been validated, and will not be reported. Thus, the registered outcome definition is not itself evidence of a measured treatment difference.
The adverse-event counts are descriptive and do not account for potentially different baseline characteristics, follow-up, or event ascertainment across groups. The record explicitly warns that the treatment arms are not like-for-like controls. It does not report an adjustment strategy, comparative effect estimates, confidence intervals, or hypothesis tests. The event counts should not be interpreted as causal effects or as a balanced safety comparison.
In general, an observational study can describe experience in clinical practice and may provide useful context, but a causal treatment comparison requires careful attention to treatment selection, confounding, measurement, and missing data. The registry entries available for this study do not resolve those concerns. The record also does not report enough information to assess the robustness of results under alternative analysis choices.
Accordingly, the defensible conclusion is limited to what the registry records: a completed observational study with three treatment groups, a defined baseline severity measure, registered additional outcomes, and reported adverse-event counts. Comparative clinical results and their statistical precision are not reported in the registry record. No conclusion about whether a treatment works or does not work follows from the information presented.
13. Why This Trial Matters Statistically
This study illustrates why the design label and the reported outcome data both matter when reading clinical research. ACCESS-Europe is explicitly described as observational, and the registry says allocation is not stated and the treatment arms are not like-for-like controls. Group labels alone therefore do not establish a fair basis for attributing differences to treatment. Any comparison must consider how patients entered each treatment group and whether important prognostic factors were measured and addressed.
The study also highlights the difference between an outcome being registered and its results being available. MR severity is described in detail, including echocardiographic assessment and an ordinal grading scale, but the registry record does not report the primary outcome values. It further says severity was not consistently captured in the comparator groups. A well-defined measure is useful, but it cannot answer a comparative question without reported observations that are sufficiently complete and comparable.
Another statistical lesson concerns missingness and analysis populations. The record gives an exclusion total for the primary analysis population and lists several reasons, but the final reason is truncated and the outcome-specific denominators are not reported. Readers therefore cannot determine from this record how the available observations relate to enrollment or how missingness may have affected the analyses.
Finally, adverse-event counts and listed outcome measures are not substitutes for a transparent comparative analysis. The registry lists 22 outcome measures and 0 analyses, while comparative estimates, uncertainty intervals, and analysis methods are not reported in the record. These distinctions help prevent descriptive counts from being overread as causal evidence and make clear why methods and complete results are essential to statistical interpretation.
14. Limitations
- The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
- Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.
The registry record does not report the primary MR severity values, despite defining the endpoint and its baseline timeframe. Severity was not consistently captured in the Medical Management and Mitral Valve Surgery groups, and those comparator values will not be reported. This prevents a complete baseline severity comparison across the listed groups using the record’s primary outcome.
The study is observational, allocation is not stated, and the record warns that treatment arms are not like-for-like controls. The clinical criteria that determined treatment and the methods used to address confounding are not reported in the registry record. Accordingly, treatment-group differences cannot be interpreted as causal from the available information.
The record describes comparator clinical outcomes at follow-up as limited and not validated and says those outcomes will not be reported. It does not give outcome-specific follow-up completeness or denominators. The primary-outcome population description identifies 240 exclusions and several reasons, but its final reason is incomplete. The missing-data approach and sensitivity analyses are not reported in the registry record.
There are also limits in assessing the adverse-event entries. The record supplies counts and lists selected serious-event terms with percentages, but the denominator for the term percentages, event observation time, event ascertainment details, and category-overlap rules are not reported. Comparative models and uncertainty estimates are likewise not reported.
The record lists 22 outcome measures and 0 analyses, and does not provide the analysis plan or a multiplicity strategy. The detailed design of the two phases and the study’s sample-size justification are not reported in the registry record. Together, these gaps limit assessment of precision, analysis choices, and the completeness and comparability of the reported outcomes.
15. Related Tutorials
16. Related Statistical Calculators
17. Sources
- ClinicalTrials.gov: ACCESS-Europe A Two-Phase Observational Study of the MitraClip® System in Europe — NCT01288976.
- Registry record last updated 2018-11-07; status last verified 2018-11.
- Results first posted 2017-12-18.
- Data retrieved from ClinicalTrials.gov on 2026-11-09.
- Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.
Continue through the Clinical Biostats statistical pathway
Use this trial's endpoint as a starting point for deeper study of effect measures, confidence intervals, and sample-size planning.
18. Record Summary
ACCESS-Europe is a completed observational study of the MitraClip System in Europe, sponsored by Abbott Medical Devices. The registry lists enrollment of 721, mitral valve regurgitation as the condition, and three treatment groups: MitraClip Therapy, Medical Management, and Mitral Valve Surgery. Its stated primary outcome is baseline MR severity assessed by echocardiography and expressed as the percentage of participants.
The record defines the severity scale but does not report primary outcome values. It says severity was not consistently captured in the comparator groups and that comparator clinical outcomes at follow-up are limited, unvalidated, and will not be reported. Adverse-event counts are recorded for each group, but the registry cautions that the arms are not like-for-like controls. It lists 22 outcome measures and 0 analyses. Comparative clinical effects, uncertainty estimates, analysis methods, and a complete account of the primary analysis population are not reported in the registry record.